MedTrace Logo

The Effect of Deep Friction Massage on the Achilles Tendon Blood Flow

NCT01453543 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2011-11-08

No results posted yet for this study

Summary

Background: There is a hypothesis in literature that the mechanical action of deep transverse friction massage (DTF) produces vasodilatation and increases blood flow. But as yet, no experimental study has confirmed the effect of DTF on blood flow in the Achilles tendon. Objective: The purpose of the present study was to investigate whether one session of DTF can influence the Achilles tendon blood flow.

Design: a randomized pre- posttest trial was set up. Patients: Sixty-two healthy participants volunteered. Each person underwent the following four steps of the procedure: 1. Measuring the tendon blood flow (PRE), 2.fifteen minutes of DTF on the Achilles tendon, 3. Measuring of the tendon blood flow (POST), 4.follow - up measurement after 20 minutes of rest (POST20).

Intervention: one leg of each person was randomly assigned to deep transverse friction session, the other leg was used as a control leg. Friction was applied continuously for a total of 15 minutes. Measurements: the microcirculation was determined at 2 and 8 tissue depths at the distal and the proximal midportion of the Achilles tendon. For each level, the capillary blood flow, the tissue oxygen saturation, and the postcapillary venous filling pressure was registered.

Conditions

  • Healthy Situation

Interventions

OTHER

deep transverse friction massage

For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.

Sponsors & Collaborators

  • University Ghent

    lead OTHER

Principal Investigators

  • Erik Witvrouw, MD, PhD · University Ghent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01453543 on ClinicalTrials.gov